Novocure (NVCR) Earnings Analysis
Novocure (NVCR) next reports earnings on 2026-10-29, consensus EPS -0.28 USD. Last quarter (2026-07-23) it beat with EPS -0.13 USD vs -0.33153 USD est (+60.8%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E -10.18.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NVCR next report earnings?
| Next earnings date | 2026-10-29 |
|---|---|
| Consensus EPS estimate | -0.28 USD |
| Revenue estimate | 0.18B |
NVCR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-07-23 | -0.13 USD | -0.33153 USD | +60.8% | Beat |
| 2026-04-30 | -0.62 USD | -0.51219 USD | -21% | Miss |
| 2026-02-26 | -0.22 USD | -0.41 USD | +46.3% | Beat |
| 2025-10-30 | -0.33 USD | -0.42 USD | +21.4% | Beat |
| 2025-07-24 | -0.36 USD | -0.39 USD | +7.7% | Beat |
| 2025-02-27 | -0.61 USD | -0.34 USD | -79.4% | Miss |
| 2024-07-25 | -0.31 USD | -0.4 USD | +22.5% | Beat |
Beat rate: 5/7 (71%) over reported quarters with consensus data.
NVCR valuation and analyst view
| Trailing P/E | -10.18 |
|---|---|
| Trailing EPS | -1.51595 USD |
| Price / book | 5.37 |
| Dividend yield | 0.00% |
| Market cap | 1.77B |
| Analyst consensus | Buy (9 buy / 5 hold / 1 sell) |
| Avg price target | 46 USD |
Related research pages
Frequently asked questions
When is Novocure (NVCR)'s next earnings date?
Novocure is next scheduled to report on 2026-10-29, with a consensus EPS estimate of -0.28 USD and revenue estimate of 0.18B.
Did NVCR beat earnings last quarter?
In its 2026-07-23 report, NVCR posted EPS of -0.13 USD versus a -0.33153 USD estimate — a beat of 60.8%.
What is NVCR's earnings track record?
Over the last 7 reported quarters with consensus data, NVCR beat estimates 5 times (71%).
What is NVCR's current P/E ratio and EPS?
NVCR trades at a trailing P/E of -10.18 on trailing EPS of -1.5159548452447213 USD.
What do analysts rate NVCR?
Analyst consensus is "Buy" across 15 ratings (0 strong buy, 9 buy, 5 hold, 1 sell, 0 strong sell). Average 12-month price target: 46 USD.